Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone.

Laboratoire de Virologie et Pathogenèse Humaine, Université Lyon 1, CNRS FRE 3011, Lyon, France.
Antiviral therapy (Impact Factor: 3.07). 02/2009; 14(1):55-61.
Source: PubMed

ABSTRACT We have previously reported that human adenovirus (HAdV) reference strains clearly show species-dependent resistance to ribavirin, whereas different species of HAdV are equally sensitive to cidofovir. All the serotypes tested were susceptible to cidofovir, whereas only serotypes from species C were sensitive to ribavirin. Here, we aimed to extend these investigations to clinical isolates.
In vitro, we tested 126 isolates obtained from 65 patients included in a European survey of HAdV infection.
Among the 126 isolates tested, all presented cidofovir 50% inhibitory concentration (IC50) in the same range as the HAdV 5 reference strain. Regarding ribavirin, all isolates from species C (79 tested) showed an IC50 comparable with previously reported results for reference strains; however, 24/32, 2/6 and 3/3 tested isolates from species A, B and D, respectively, were shown to have a ribavirin IC50 comparable with the HAdV 5 reference strain (species C), contrary to previous observations for reference strains of the same species. Among patients who were treated with cidofovir for disseminated HAdV infection, > or = 4 sequential isolates could be obtained from 9 patients; no variation in cidofovir susceptibility could be detected.
Cidofovir is active in vitro in all HAdV clinical isolates. Ribavirin was revealed to be active on most HAdV isolates from species A, B and D, and in all isolates from species C. Finally, no resistance to cidofovir became apparent in sequential isolates obtained from treated patients.

1 Bookmark

Full-text (2 Sources)

Available from
May 26, 2014